NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $33.92 +0.84 (+2.54%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$32.64▼$34.3150-Day Range$33.08▼$46.6552-Week Range$28.54▼$54.85Volume611,263 shsAverage Volume529,673 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$66.38Consensus RatingModerate Buy Company Overview Harrow, Inc. is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing products for the treatment of eye conditions and for use in ophthalmic procedures. The company serves ophthalmologists, optometrists, ambulatory surgery centers, and other eye-care providers, primarily in the United States. Harrow’s portfolio includes VEVYE, a cyclosporine ophthalmic emulsion indicated for the treatment of signs and symptoms of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used to provide topical ocular anesthesia during ophthalmic procedures. The company also markets and develops additional prescription ophthalmic products and therapies through its commercial and pharmaceutical operations. The company was founded as Harrow Health and later adopted the Harrow name as it expanded its ophthalmic pharmaceutical business. Harrow is headquartered in Nashville, Tennessee, and is led by founder and Chief Executive Officer Mark L. Baum.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 34% of companies evaluated by MarketBeat, and ranked 704th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialHarrow has a consensus price target of $66.38, representing about 95.7% upside from its current price of $33.92.Amount of Analyst CoverageHarrow has only been the subject of 4 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -33.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -33.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 24.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.74% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 13.69, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently increased by 6.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Harrow this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Harrow to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,000.00 in company stock.Percentage Held by Insiders12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesCritical Comparison: Rafael (NYSE:RFL) & Harrow (NASDAQ:HROW)September 21 at 6:45 AM | americanbankingnews.comHarrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo FinanceSeptember 15, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 21 at 1:00 AM | Stansberry Research (Ad)Harrow (NASDAQ:HROW) Research Coverage Started at Leerink PartnersSeptember 12, 2026 | americanbankingnews.comLeerink Partners initiates coverage of Harrow at outperformSeptember 10, 2026 | msn.comLeerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price TargetSeptember 9, 2026 | marketscreener.comMHarrow Health Streamlines Senior Finance and Accounting LeadershipSeptember 4, 2026 | tipranks.comHarrow to Participate in Three Investor Conferences in SeptemberSeptember 1, 2026 | globenewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $49.00 at the beginning of the year. Since then, HROW shares have decreased by 30.8% and is now trading at $33.92. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) released its earnings results on Monday, August, 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.28. The company earned $70.66 million during the quarter, compared to the consensus estimate of $70.35 million. Harrow had a negative trailing twelve-month return on equity of 38.00% and a negative net margin of 13.51%. Read the conference call transcript. Who are Harrow's major shareholders? Top institutional shareholders of Harrow include BlackRock Inc. (7.35%), Opaleye Management Inc. (6.40%), Bamco Inc. NY (2.16%) and Jupiter Topco LLC (1.54%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Amir Shojaei and Adrienne L Graves. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/10/2026Today9/21/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, HROW's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrow.com Phone(615) 733-4730Fax858-345-1745Employees373Year Founded2012Price Target and Rating Average Price Target for Harrow$66.38 High Price Target$88.00 Low Price Target$45.00 Potential Upside/Downside+95.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.14 million Net Margins-13.51% Pretax Margin-12.13% Return on Equity-38.00% Return on Assets-3.37% Debt Debt-to-Equity Ratio19.70 Current Ratio2.24 Quick Ratio2.08 Sales & Book Value Annual Sales$272.30 million Price / Sales4.67 Cash Flow$0.89 per share Price / Cash Flow38.27 Book Value$1.41 per share Price / Book24.06Miscellaneous Outstanding Shares37,490,000Free Float32,690,000Market Cap$1.27 billion OptionableOptionable Beta0.24 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:HROW) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts